KC
OACCU

Kepos Capital’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

Kepos Capital’s Portfolio OACCU Stock Details OACCU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70,000
Closed -$709K – 65
2024
Q4 		$709K Buy
+70,000
New +$705K 0.61% 14

Other funds holding OACCU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
LIP
Lighthouse Investment Partners Palm Beach Gardens, Florida $2.87B AUM 26.77% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kepos Capital's OACCU Position: Q1 2025 in Review

Kepos Capital sold out of Oaktree Acquisition Corp III Life Sciences Unit (OACCU) in Q1 2025, closing a stake of 70,000 shares — an estimated $709K sold.

Kepos Capital first reported a position in OACCU in Q4 2024 and held it in 1 quarter. The position peaked at $709K in Q4 2024. 11 funds tracked by Wall St. Rank hold OACCU as of Q1 2025.

  • Kepos Capital reported no remaining Oaktree Acquisition Corp III Life Sciences Unit position as of Q1 2025 after selling out during the quarter.
  • Kepos Capital sold 70,000 Oaktree Acquisition Corp III Life Sciences Unit shares in Q1 2025, an estimated $709K.
  • Kepos Capital first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and held it in 1 quarter.
  • Kepos Capital's Oaktree Acquisition Corp III Life Sciences Unit position peaked at $709K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q1 2025.

Based on Kepos Capital's 13F filing for Q1 2025, filed 13 May 2025.